Novo Nordisk's Mixed Signals: A Legal Win, a Raised Outlook, and a Market That Can't Quite Decide
Published on 08/09/2026 at 13:22 | Redaktion boerse-global.de
The Danish pharmaceutical heavyweight finds itself in an unusual position: delivering better-than-feared numbers while simultaneously absorbing setbacks that would have rattled the stock in calmer times. Novo Nordisk's second-quarter results for 2026, released on a Tuesday, showed revenue of 78.5 billion Danish kroner—a 7 percent increase on a currency-adjusted basis—and prompted management to narrow its full-year guidance to a range of 0 to minus 6 percent growth in both sales and operating profit. That marks a meaningful improvement from the previous, far gloomier projection of minus 4 to minus 12 percent, yet the initial market reaction was muted at best.
The Pill Is Winning, Even as Margins Slip
The real story emerging from the quarterly numbers is the rapid ascent of the oral Wegovy tablet. Novo Nordisk has now recorded more than five million prescriptions for the pill, capturing roughly 90 percent of the US oral GLP-1 market. Perhaps more tellingly, 80 percent of patients switching to the oral formulation are entirely new to the GLP-1 category—suggesting the company is expanding the addressable patient pool rather than merely cannibalizing its own injectable franchise. International obesity sales climbed 37 percent, underscoring the global reach of this shift.
That growth, however, comes at a cost. Gross margin contracted to 78.2 percent in the quarter, down from 82.7 percent a year earlier, as pricing pressure and intensifying competition in the obesity space take their toll. The pipeline also delivered a fresh disappointment: the ZEUS study evaluating Ziltivekimab, a cardiovascular candidate, missed its primary endpoint with a hazard ratio of 0.99—essentially no benefit over placebo.
Investors are now pinning their hopes on CagriSema, the combination therapy that represents the company's most significant near-term catalyst. Novo Nordisk anticipates US approval by the end of 2026, with a market launch slated for 2027—a timeline that appears tighter than many analysts had expected given the setbacks the obesity pipeline has endured.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Legal Victory in the Compounding Wars
On the legal front, the company secured a notable win in the Netherlands, where a Dutch court granted a preliminary injunction against Ceban Ziekenhuisfarmacie, a pharmacy chain that had been manufacturing and distributing an unauthorized semaglutide nasal spray. The ruling halts production and sales in the country, marking a victory in the broader battle against compounding pharmacies that produce copies of patented GLP-1 drugs. While this decision may not move the needle on the stock in the near term, it bolsters Novo Nordisk's position in the ongoing fight to protect its intellectual property.
The Competitive Arithmetic Gets Harder
The elephant in the room remains Eli Lilly. The US rival reported second-quarter revenue of 23.0 billion dollars, a 48 percent surge, powered by Mounjaro's 91 percent jump to 9.9 billion dollars and Zepbound's 46 percent gain to 4.9 billion dollars. Lilly raised its full-year outlook to 85–87 billion dollars and unveiled positive Phase 3 data for Retatrutide, with a regulatory submission planned for the first quarter of 2027. Novo Nordisk still dominates the oral GLP-1 segment, but the velocity of Lilly's growth suggests the market-share battle will only intensify.
Adding to the pressure are structural headwinds: reports of dual patent setbacks for semaglutide in both the EU and the US, alongside deeper-than-announced job cuts in Denmark, have compounded the sense of a company navigating multiple fronts simultaneously.
Reading the Tape
The stock's behavior on Friday offered a window into investor psychology. Shares closed at 40.99 euros in Germany, up 2.69 percent on the day, with no single company announcement driving the move. Mads Zink, chief trader at Danske Bank, attributed the rally to three factors: broad strength across European pharma, a reassessment of the prior decline as an overreaction, and a confluence of reinforcing elements. The advance came despite the disappointing Ziltivekimab data disclosed the previous Thursday, suggesting the market is beginning to separate operational momentum from pipeline noise.
Since the interim results were published on Tuesday, the stock has gained 6.6 percent. Yet the longer-term picture remains sobering. The share price sits roughly a quarter below its 52-week high of 54.86 euros, reached in January, even after recovering more than 35 percent from its March trough. Year-to-date, the stock is still down nearly 7 percent—a disconnect between the operational story and the market's verdict.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A Jyllands-Posten analysis calculated that Novo Nordisk has shed around 3,000 billion Danish kroner in market capitalization, though the newspaper concluded the Danish economy remains largely insulated from that decline. The framing was characteristically vivid: Novo Nordisk missed a great opportunity, but the decisive chapter has yet to be written.
A Valuation Question for the Next Earnings Cycle
Trading at a price-to-earnings ratio of roughly 11.6 against a European pharma sector average of about 21.9, the stock carries a substantial discount. Whether that gap is justified—given margin erosion and competitive pressure—will likely be settled by the coming quarters, particularly by how swiftly CagriSema moves from approval to commercial launch. For now, the company counts 46 million patients with obesity or diabetes, with five million on obesity therapies, a 70 percent increase year over year. Those numbers provide the counterweight to pipeline disappointments and help explain why some institutional investors view the recent weakness as an entry point rather than an exit signal.
Technically, the picture remains ambiguous: the stock sits almost exactly on its 50-day moving average, with the short-term recovery intact but a long way from the year's highs. The Dutch legal victory strengthens the intellectual property position, but the market's attention will remain fixed on the competitive race and the pipeline's ability to deliver on its promises.
Ad
Novo Nordisk Stock: New Analysis - 9 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
